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Plant pathogenic Pseudomonas syringae deliver type III effector
proteins into the host cell, where they function to manipulate host
defense and metabolism to benefit the extracellular bacterial
colony. The activity of these virulence factors can be monitored by
plant disease resistance proteins deployed to ‘‘guard’’ the targeted
host proteins. The Arabidopsis RIN4 protein is targeted by three
different type III effectors. Specific manipulation of RIN4 by each of
them leads to activation of either the RPM1 or RPS2 disease
resistance proteins. The type III effector AvrRpt2 is a cysteine
protease that is autoprocessed inside the host cell where it acti-
vates RPS2 by causing RIN4 disappearance. RIN4 contains two sites
related to the AvrRpt2 cleavage site (RCS1 and RCS2). We demon-
strate that AvrRpt2-dependent cleavage of RIN4 at RCS2 is func-
tionally critical in vivo. This event leads to proteasome-mediated
elimination of all but a membrane-embedded 6.4-kDa C-terminal
fragment of RIN4. One or more of three consecutive cysteines in
this C-terminal fragment are required for RIN4 localization; these
are likely to be palmitoylation andor prenylation sites. AvrRpt2-
dependent cleavage at RCS2, and release of the remainder of RIN4
from the membrane, consequently prevents RPM1 activation by
AvrRpm1 or AvrB. RCS2 is contained within the smallest tested
fragment of RIN4 that binds AvrB in vitro. Thus, at least two
bacterial virulence factors target the same domain of RIN4, a
30-aa plant-specific signature sequence found in a small Arabi-
dopsis protein family that may be additional targets for these
bacterial virulence factors.
disease resistance  plant immune system
P lant disease resistance (R) genes control the plant immuneresponse upon pathogen recognition. R proteins initiate
cellular events that efficiently limit pathogen reproduction (1).
Most plant R proteins defined to date possess a central nucle-
otide binding (NB) domain together with C-terminal leucine-
rich repeats (LRR), and hence are termed NB-LRR proteins.
NB-LRR proteins are specific in that each is activated by a
particular pathogen-encoded molecule. These are polymorphic
across the pathogen population. The proteins from Gram-
negative plant-pathogenic bacteria that trigger NB-LRR action
are type III effector proteins delivered into plant cells through
the type III secretion system (2). These are called avirulence
(Avr) proteins because their presence renders a given pathogen
strain avirulent on a resistant plant genotype (R). Avr proteins,
however, can also contribute to pathogen virulence on suscep-
tible plant genotypes (r).
An Avr ligand-R receptor model could explain the genetic
specificity of disease resistance, although experimental support
for this model is limited. Rather, accumulating evidence suggests
that Avr proteins from pathogenic bacteria can be recognized
indirectly by their action on one or more host targets (1, 3, 4).
In this model, type III effector proteins manipulate host targets,
thereby contributing to pathogen virulence. The plant NB-LRR
protein, if present, senses the outcome of this manipulation,
activating host defenses. This ‘‘guard hypothesis’’ explains the
action of several NB-LRR proteins, including the two discussed
here, RPM1 (resistance to P. syringae pv. maculicola) and RPS2
(resistance to P. syringae) (5–7).
RPM1 interacting protein 4 (RIN4) is a small (211 aa) protein
that, along with RPM1 and RPS2, is localized to the plasma
membrane (8–10). RIN4 associates with both RPM1 and RPS2
in yeast two-hybrid and coimmunoprecipitation experiments
from plant extracts (9, 11, 12). RPM1 is activated by either of the
unrelated AvrRpm1 or AvrB type III effector proteins. Both
AvrRpm1 and AvrB are acylated in the host cell after type III
secretion system delivery and hence are targeted to the plasma
membrane (13). Infection of both RPM1 and rpm1 plants with P.
syringae expressing either AvrB or AvrRpm1 leads to phosphor-
ylation of RIN4. RIN4 phosphorylation is correlated with RPM1
activation (9). RIN4 is also targeted by a third type III effector,
AvrRpt2, which encodes a cysteine protease (12). Delivery of
AvrRpt2 into plant cells results in its autoprocessing and acti-
vation (14), which in turn leads to RIN4 disappearance and
consequent activation of RPS2 (11, 12). Thus, three different
type III effectors use at least two different mechanisms to
manipulate RIN4, and thereby regulate the activation of two
different NB-LRR proteins. In the absence of RIN4, RPS2 is
activated to an extent that is lethal (9), whereas RPM1 is weakly
activated, suggesting that RIN4 has a formal negative regulatory
effect on both RPS2 and RPM1 (15). Despite its importance in
regulation of RPM1 and RPS2, RIN4 is dispensable for the
virulence function of AvrRpm1 and AvrRpt2 in disease-
susceptible rin4 rpm1 rps2 plants, suggesting the existence of
additional host cellular targets (15).
Delivery of AvrRpt2 interferes with AvrRpm1- or AvrB-
dependent activation of RPM1 (16), suggesting that these three
type III effectors compete for a common factor required for
RPM1 function. The isolation of RIN4 offers the opportunity to
test directly the hypothesis of whether AvrRpt2-dependent
cleavage and subsequent elimination of RIN4 from the plasma
membrane interferes with AvrRpm1- or AvrB-dependent acti-
vation of RPM1. We also examine the requirements for RIN4
cleavage by AvrRpt2 and the means by which RIN4 is localized
to the plasma membrane.
Materials and Methods
Bacterial Inoculations. Hypersensitive response (HR) and growth
restriction assays were as described (15).
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Site-Directed PCR-Mediated Mutagenesis. Mutations in RIN4
(At3g25070) were generated by PCR-based site-directed mu-
tagenesis using PFU turbo high-fidelity polymerase (Strate-
gene). Complementary PCR forward and reverse primers were
used for mutagenesis of RIN4 (see Supporting Materials and
Methods, which is published as supporting information on the
PNAS web site, for details).
Transgenic Plants. RIN4 mutant derivatives were cloned into
binary vector pTA7002 (17). Agrobacterium tumefaciens
(GV3101) carrying pTA7002 with each RIN4 derivative were
vacuum-infiltrated into flowering Arabidopsis rin4 rps2 RPM1 or
rin4 rps2 rpm1 plants (15). Basta (AgroEvo, Frankfurt, Ger-
many) was sprayed on 1-week-old T1 seeds to select for trans-
genic progeny. All analyses of transgenic plants were carried out
by using Basta-resistant T2 lines treated with 20 M dexameth-
sone (DEX) (9).
Protein. Two to three leaves of 2 cm2 were ground in sucrose
buffer (20 mM Tris, pH 8.00.33 M sucrose1 mM EDTA1
Sigma protease inhibitor mixture) and centrifuged at 2,000  g,
and the supernatant was collected as the total protein extract.
Half of the total extract was centrifuged at 20,000  g, resulting
in soluble fraction and microsomal membrane fractions. Protein
concentrations of total, soluble, and microsomal membrane
fractions were equalized by using 6 loading buffer (120 nM
Tris, pH 8.650% glycerol6% SDS2% 2-mercaptoethanol).
Samples were separated by 12% SDSPAGE and transferred
onto nitrocellulose membranes for Western detection (ECL kit;
Amersham Pharmacia Biosciences). Anti-RIN4 sera (9) was
used at 1:5,000 in 1 TTBS (1 M Tris, pH 8.05 M NaCl0.05%
Tween 201% milk powder). The proteasome inhibitor clasto-
lactacysteine -lactone (Calbiochem; 20 M in 1% DMSO) was
hand-inoculated into leaves.
2-Bromopalmitic Acid (2-BPA) Treatment of Arabidopsis Plants.
Leaves of 3-week-old rin4 rps2 RPM1 plants were hand-
inoculated with 2-BPA (Sigma-Aldrich) at 100 M in 1%
DMSO. Plants were sprayed with 20 M DEX 1 h after 2-BPA
treatment. Leaves were harvested 24 h later and fractionated
into total, soluble, and membrane fractions as described above.
Proteins were separated by 12% SDSPAGE for Western blot
analysis.
In Vitro AvrB-RIN4 Binding Assays. AvrB was cloned from P. syringae
pv. glycinea with an N-terminal histidine tag and transformed
into BL21CodonPlus (DE3)-RIL cells (Stratagene). Expressed
protein was purified on high-trap chelating columns according to
the manufacturer’s instructions (Amersham Pharmacia Bio-
sciences; see Supporting Materials and Methods for details). RIN4
fragments were amplified by PCR, subcloned as N-terminal
GST-fusion proteins by using Gateway pDEST-15 vector (In-
vitrogen), and transformed into BL21CodonPlus (DE3)-RIL
cells (Stratagene). Fusion proteins were purified by using Glu-
tathione Sepharose 4B (Amersham Pharmacia Biosciences; see
Supporting Materials and Methods for details).
For native gel electrophoresis, AvrB was mixed with a purified
GST-RIN4 fragment, incubated on ice, and run on a Homoge-
neous 12.5 PhastGel (Amersham Pharmacia Biosciences) by
using a Phast System (Amersham Pharmacia). For gel filtration
analysis, isolated RIN4142–179 peptide was mixed with AvrB, and
the mixture was separated by using a calibrated hand-poured XK
1670 Superdex 75 (Amersham Pharmacia) column equilibrated
in 20 mM Hepes (pH 7.5), 150 mM NaCl, and 2 mM DTT.
Five-milliliter fractions were collected and analyzed by SDS
PAGE (see Supporting Materials and Methods for details).
Results
AvrRpt2 Cleaves RIN4. AvrRpt2 has a cysteine protease cleavage
site similar to the catalytic core of staphopains (CA clan)
cysteine proteases (12). AvrRpt2 is amino-terminally processed
in plant cells into 7- and 21-kDa fragments; the latter is the
protease (14). Mutations in the conserved catalytic core of
AvrRpt2 prevented autoproteolysis and both RIN4 degradation
and RPS2 activation (12). RIN4 contains two sites related to the
AvrRpt2 autocleavage site (Fig. 1A), termed RCS (AvrRpt2
cleavage site) 1 (V6-W12) and RCS2 (V148-W154) (Fig. 1B and
ref. 18). Using GST-RIN4 fusion proteins, we demonstrated that
the presence of catalytically active AvrRpt2 and an unknown
factor present in Arabidopsis extracts led to the appearance of
Fig. 1. RIN4 contains two cysteine protease cleavage sites. (A) A consensus
cysteine protease cleavage site is present in both RIN4 and AvrRpt2. Block
mutations to alanine discussed below were made in the underlined residues,
V–FG-W. (B) RIN4 amino acid sequence features: RCS1 (V6-W12), RCS2 (V148-
W154), and a putative palmitoylation site at C203–C205 are underlined. The
fragment from P142 to G179 (end points underlined) is discussed in the Fig. 6
legend. (C) Overexpression of proteolytically active AvrRpt2 leads to RIN4
cleavage and accumulation of a C-terminal RIN4 fragment. Col-0 transgenic
plants conditionally overexpressing AvrRpt2 were treated with 20 M DEX,
and total extracts were prepared from leaves harvested at the indicated time
points indicated (hours post-DEX) for SDSPAGE and Western blot with anti-
RIN4 sera. (D) Delivery of enzymatically active AvrRpt2 from P. syringae
specifically results in accumulation of a 6.4-kDa membrane-bound RIN4 frag-
ment, consistent with cleavage at RCS2. Col-0 plants were infected with 5 
107 colony-forming unitsml of Pto DC3000 carrying either avrRpt2 or a
protease dead mutant avrRpt2C122A. Protein samples from the membrane
microsomal fraction were tested by protein blot with anti-RIN4 sera at 0, 4, and
8 h postinfection.









appropriately sized RIN4 fragments (data not shown and Sup-
porting Materials and Methods).
A C-Terminal, AvrRpt2-Dependent Cleavage Product of RIN4 Is
Membrane-Localized. Our in vitro data suggested that both RIN4
RCS1 and RCS2 (Fig. 1 A and B) can be cleaved by AvrRpt2. We
reasoned that cleavage of RIN4 by AvrRpt2 might lead to the
disappearance of some or all of the RIN4 products from the
plant microsomal membrane fraction (hereafter membrane).
Cleavage at RCS1 would result in 22.2- and 1.2-kDa fragments,
cleavage at RCS2 would result in fragments of 17 and 6.4 kDa,
and cleavage at both RCS1 and RCS2 would result in fragments
of 15.9, 6.4, and 1.2 kDa. Conditional overexpression (using a
DEX-inducible transgene; see Materials and Methods) of WT
AvrRpt2 led to RIN4 cleavage and the accumulation over time
of a 6.4-kDa RIN4 fragment, consistent with the predicted RIN4
C-terminal fragment remaining after cleavage at RCS2 (Fig.
1C). The same-sized RIN4 fragment was seen exclusively in the
membrane fraction after delivery of WT AvrRpt2 to plant cells
from P. syringae starting at 4 h postinoculation. This fragment did
not appear after the delivery of a catalytically inactive AvrRpt2
C122A mutant (Fig. 1D). Appearance of this 6.4-kDa RIN4
fragment suggests that at least RCS2 is cleaved in vivo and
further suggests that the C-terminal cleavage product remains
membrane localized. A faint 16-kDa fragment was also observed
in the soluble fraction, but only when leaves were pretreated with
proteasome inhibitors (data not shown). It is likely that the
N-terminal cleavage fragment of 1.2 kDa would not be detected
in these experiments.
The C-Terminal Region of RIN4 Determines Its Localization by Three
Cysteine Residues That Are Likely Palmitoylation andor Prenylation
Sites. To analyze the functional consequences of RIN4 proteol-
ysis at either RCS1 or RCS2, we made three sets of RIN4 mutant
derivatives. We mimicked RIN4 cleavage at RCS1 with
RIN411–211, cleavage at RCS2 with RIN41–152, and cleavage at
both RCS1 and RCS2 with RIN411–152 (Fig. 2A). Transgenic
plants conditionally expressing these derivatives were made in
rin4 rps2 RPM1. A WT C terminus was required for proper RIN4
localization, because RIN41–152 and RIN411–152 were found only
in the soluble fraction, and RIN411–211 localized only to the
membrane fraction (Fig. 3A). The conditional RIN4 expression
levels were not significantly different from WT RIN4 in any
experiments (data not shown, but see Fig. 4B).
The C-terminal region of RIN4 contains possible palmitoyl-
ation andor prenylation sites at C203, C204, and C205 (Fig. 1B).
Posttranslational acylation of any of these cysteines could drive
membrane association andor integration of RIN4 into lipid
microdomains within the plasma membrane (19). We created
the RIN4C203AC204AC205A mutant (Fig. 2). Membrane and sol-
uble fractions from two independent rin4 rps2 RPM1 trans-
genic lines conditionally expressing either WT RIN4 or
RIN4C203AC204AC205A were analyzed. As expected, WT RIN4 is
in the membrane fraction (Fig. 3 B and C). We could not detect
any RIN4C203AC204AC205A in these extracts unless we inoculated
a proteasome inhibitor at the time of DEX induction (compare
Fig. 3 B with C). Thus, C203, C204, and C205 are required for
RIN4 localization, and RIN4C203AC204AC205A is rapidly degraded
via the proteasome.
We used a palmitoylation inhibitor, 2-BPA (Materials and
Methods; ref. 19), to test whether palmitoylation of RIN4
contributes to its membrane localization. Infiltration of 2-BPA
into leaves of transgenic plants before DEX treatment signifi-
cantly reduced RIN4 accumulation in the membrane fraction, as
compared with untreated or mock-treated leaves (Fig. 3D).
Further, 2-BPA treatment eliminated RIN4 accumulation from
the soluble fraction (data not shown). This result suggests that
one or more of the cysteines at C203, C204, and C205 are
palmitoylated, this acylation is responsible for efficient RIN4
localization, and full-length RIN4 is destabilized in the absence
of acylation. Despite their genotype, the rin4 rps2 RPM1 plants
used for our transgenics do not generate an AvrRpm1-driven
HR because diminution of RIN4 levels leads to proportional
reduction in RPM1 accumulation (9). Consistent with these
findings, DEX-treated RIN4C203AC204AC205A plants did not ex-
press an RPM1-dependent HR after inoculation with
DC3000(avrRpm1), whereas DEX-treated RIN4 plants did (data
not shown).
RIN4 Mutants in RCS1 and RCS2 Retain Proper Membrane Localization,
and AvrRpt2 Cleavage at RCS2 Is Required for RIN4 Disappearance.
We ultimately wanted to test whether AvrRpt2-dependent cleav-
age of RIN4 from the plasma membrane perturbs RPM1
activation by AvrRpm1. First, we conditionally expressed RIN4
mutants that have alanine substitutions at either RCS1 or RCS2
or both (Figs. 1 A and B and 2) in rin4 rps2 RPM1 transgenic
plants. We did not change the conserved RCS proline to avoid
possible structural disruption. Mutation of the RCS sites did not
alter membrane localization of these RIN4 derivatives, because
all three accumulated only in the membrane fraction (Fig. 4A).
We inoculated DEX-treated plants expressing WT RIN4,
RIN4RCS1, RIN4RCS2, or RIN4RCS1–2 with either Pseudomonas
syringae pv. tomato (Pto) DC3000(EV), Pto DC3000(avrRpt2), or
Pto DC3000(avrRpt2C122A). AvrRpt2 caused disappearance of
Fig. 2. RIN4 mutant derivative constructs used to test the effect of RIN4
proteolysis on RPM1 activation and AvrRpt2 virulence function. Two sets of
conditionally expressed constructs to express mutant RIN4 proteins are shown.
(A) The 211-aa RIN4 protein is schematically shown at the top. Putative
AvrRpt2 cleavage sites follow G10 and G152. Putative palmitoylation sites at
C203, C204, and C205 are denoted by a gray box. RIN4 derivatives that mimic
the putative products of AvrRpt2-mediated cleavage were constructed: the
larger product from N-terminal cleavage, termed RIN411–211, the product
ending at the C-terminal cleavage site, RIN41–152, or the internal product of
both cleavage events, RIN411–152. (B) Alanine RIN4 block mutants that alter
AvrRpt2-mediated cleavage events at either the N-terminal cleavage site,
termed RIN4RCS1, the C-terminal cleavage site, RIN4RCS2, or both, RIN4RCS1–2 (see
Fig. 1 for consensus sequences mutated to alanine). (C) Alanine block muta-
tion (gray X) of the RIN4 putative palmitoylation site, C203AC204AC205A,
generates RIN4C203AC204AC205A.
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both the endogenous RIN4 in Col-0 and the slightly higher levels
of WT RIN4 achieved with the conditional expression system
(Fig. 4B). AvrRpt2 also drove the disappearance of RIN4RCS1.
By contrast, AvrRpt2 did not trigger disappearance of RIN4RCS2
and RIN4RCS1–2 from the membrane (Fig. 4B). As expected, the
enzymatic activity of AvrRpt2 is required for these events (Fig.
4B). Combined with data from Fig. 3, our results demonstrate
that (i) AvrRpt2 action at RCS2 is critical in vivo for RIN4
elimination and (ii) cleavage at RCS2 releases RIN4 from the
membrane, allowing subsequent proteasome-dependent elimi-
nation of the resulting fragments.
AvrRpt2-Dependent Cleavage of RCS2 Is Required to Interfere with
RPM1 Activation. Because the RIN4RCS1, RIN4RCS2, and
RIN4RCS1–2 derivatives were properly localized, we addressed
whether they supported RPM1 activation. Both RPM1-
dependent restriction of bacterial growth and RPM1-mediated
HR were restored by each RCS mutant (Fig. 5 and Fig. 7, which
is published as supporting information on the PNAS web site).
Thus, RCS mutation does not alter AvrRpm1 (or AvrB, data not
shown) activation of RPM1. Inoculation of plants expressing WT
RIN4 with Pto DC3000(avrRpm1 plus avrRpt2) neither resulted
in restricted growth (Fig. 5B), nor elicited RPM1-mediated HR
(Fig. 7) as expected (16). AvrRpt2 also blocked these AvrRpm1-
dependent responses in RIN4RCS1 plants (Fig. 5). However,
AvrRpt2 could not block either of the two AvrRpm1-dependent
responses in RIN4RCS2- or RIN4RCS1–2-expressing plants (Fig.
5). Similar results were obtained for AvrB-dependent responses
(data not shown). We conclude that AvrRpt2 cleavage of RIN4
at RCS2 is required to interfere with RPM1 activation by either
AvrRpm1 or AvrB.
The AvrB Interacting Domain of RIN4 Overlaps with the C-Terminal
Cysteine Protease Cleavage Site. AvrRpm1 and AvrB associate
with RIN4, resulting in its phosphorylation. AvrRpm1 coimmu-
Fig. 3. RIN4 is localized to the membrane by a putative palmitoylation site
at C203C204C205. (A) Membrane localization requires the RIN4 C-terminal
region. The RIN4 derivatives that mimic AvrRpt2 cleavage (Fig. 2), RIN411–211,
RIN41–152, and RIN411–152, were conditionally expressed in transgenic rin4 rps2
RPM1 plants (20 M DEX treatment) for 24 h. Protein samples from the
microsomal and soluble fractions were analyzed for presence of the respective
RIN4 fragments. (B and C) The three possible cysteine palmitoylation sites,
C203, C204, and C205 are required for RIN4 localization membrane. Condi-
tionally expressed transgenes encoding WT RIN4 or the RIN4C203AC204AC205A
block mutant (Fig. 2) were constructed in rin4 rps2 RPM1 plants. Two trans-
genic lines for each construct were tested for localization of RIN4 either in the
absence (B) or presence (C) of 20 M clasto-lactacysteine -lactone (see
Materials and Methods). (D) A palmitoylation inhibitor diminishes the amount
of RIN4 targeted to the membrane. 2-BPA (100 M) was infiltrated 1 h before
DEX treatment of transgenic rin4 rps2 RPM1 plants conditionally expressing
WT RIN4, and samples were taken 24 h later for protein blots.
Fig. 4. In vivo cleavage site of RIN4 by AvrRpt2 at RCS2 is critical. (A) Mutation
of the AvrRpt2 cleavage sites in RIN4 does not alter their proper localization
to the membrane. Membrane and soluble protein fractions were prepared
from leaves 24 h after 20 M DEX treatment of transgenic rin4 rps2 RPM1
plants conditionally expressing the proteins listed at the top (see Fig. 2). (B)
AvrRpt2-dependent cleavage at RIN4RCS2 is required for elimination of RIN4
from the membrane. Plants were treated with DEX as in A and inoculated 24 h
later with 5  105 colony-forming unitsml of Pto DC3000(EV), Pto
DC3000(avrRpt2), or Pto DC3000 (avrRpt2C122A). Leaf samples were collected
for microsomal membrane protein extraction 12 h after infection.









noprecipitates with RIN4, but direct interaction with RIN4 has
not been demonstrated. AvrB, however, interacts with RIN4 in
yeast two-hybrid assays, suggesting direct interaction (9). We
mapped the region of RIN4 that interacts directly with AvrB by
using epitope-tagged RIN4 deletion derivatives (Fig. 6A) puri-
fied from Escherichia coli extracts (see Materials and Methods).
Each purified RIN4 derivative was incubated with purified AvrB
and analyzed on native PAGE gels. We observed a molecular
weight band higher than AvrB alone only when WT RIN4,
RIN4142–211, or RIN4142–179 (Fig. 6B, indicated by *) were
incubated with AvrB. The AvrB and RIN4142–179 mixture was
loaded onto a calibrated native gel filtration column, and
fractions were collected and run on SDSPAGE. We observed
a protein complex of 44 kDa, near the expected molecular mass
of 40.4 kDa, consistent with an AvrB and RIN4142–179 complex
in fractions 5–7 (Fig. 6C).
Discussion
The Arabidopsis protein RIN4 is targeted by at least three
bacterial virulence factors. One is AvrRpt2, a cysteine protease
(12). AvrRpt2-dependent disappearance of RIN4 is required for
activation of the RPS2 NB-LRR class disease resistance protein
(10, 11). AvrRpm1 and AvrB have no easily predicted biochem-
ical function, yet their presence leads to accumulation of phos-
phorylated RIN4 and RPM1 activation. Thus, three unrelated
type III effector proteins target RIN4 by at least two different
mechanisms. Manipulation of RIN4 initiates the activation of
two different NB-LRR disease resistance proteins, RPM1 and
RPS2. In disease-susceptible plants, the same RIN4 modifica-
tions occur, presumably to manipulate host responses regulated
by RIN4. AvrRpt2 and AvrRpm1 also have additional targets
besides RIN4 in the plant cell (15). The present work was aimed
at understanding (i) whether the RCS sequences were cleaved in
vivo by AvrRpt2, (ii) how RIN4 was localized, and (iii) whether
in vivo cleavage of RCS sequences is the means by which
AvrRpt2 interferes with AvrRpm1- or AvrB-mediated activation
of RPM1 (16).
Two AvrRpt2 cleavage sites, RCS1 near the N terminus and
RCS2 near the C terminus, are found in RIN4 (Fig. 1) (18, 20).
RCS1 and RCS2 can be cleaved in vitro by AvrRpt2 in the
presence of an unidentified eukaryotic host factor (data not
shown and ref. 14). AvrRpt2 drives RIN4 disappearance from
total extracts (10, 11). We observed the AvrRpt2-driven accu-
mulation of a small membrane-localized RIN4 fragment. This
finding is consistent with cleavage at RCS2 and retention of the
remaining C-terminal RIN4 fragment in the membrane. We did
not clearly observe RIN4 fragments of sizes consistent with
cleavage at either RCS1 or both RCS1 and RCS2 in vivo, unless
we coinoculated a proteasome inhibitor. Hence, these presum-
ably soluble fragments might be very short-lived.
We demonstrated RIN4 is tethered to the membrane via
probable palmitoylation at C203, C204, andor C205. Alterna-
tively, the cluster of three cysteines near the C-terminal end of
a protein may lead to both palmitoylation and prenylation (19).
RIN4C203AC204AC205A did not accumulate in the soluble fraction
unless we included a proteasome inhibitor. In contrast, RIN4
derivatives truncated at residue 152 did accumulate in the
soluble fraction. Hence, nonacylated RIN4 is rapidly directed to
the proteasome, perhaps because it is misfolded, by signals that
include sequences between residues 153 and 211.
The RIN4RCS2 and RIN4RCS1–2 mutations abolished AvrRpt2-
dependent disappearance of RIN4 from the membrane, whereas
the RIN4RCS1 mutation did not. Thus, RCS2 is the key in vivo site
for AvrRpt2 action. RIN4RCS1, RIN4RCS2, and RIN4RCS1–2 were
properly localized and were competent for AvrRpm1- or AvrB-
mediated activation of RPM1, suggesting that neither RCS
sequence per se is required for those activities. Both the
RIN4RCS2 and RIN4RCS1–2 mutations abolished the ability of
Fig. 5. AvrRpt2-dependent cleavage at RIN4RCS2 blocks activation of RPM1 by
AvrRpm1. Plants expressing RIN4 and RCS mutant derivatives listed at the
bottom were treated with DEX (as in Fig. 4) to induce expression of WT RIN4
and RCS mutant derivatives listed below and then inoculated with 5  105
colony-forming unitsml of Pto DC3000-expressing genes listed. Bacterial
growth was measured 0 (empty bars) and 3 days (filled bars) postinoculation.
Error bars represent standard deviation from three samples. The values from
the experiment are representative of two additional replicates.
Fig. 6. The RIN4 domain that interacts with AvrB overlaps RCS2. (A) RIN4
deletion mutants were constructed and expressed in E. coli (see Materials and
Methods) to define a region sufficient for interaction with AvrB in vitro. The
location of RCS1 and RCS2 are indicated by boxes on the RIN4 sequence. (B)
Purified AvrB and RIN4 deletion derivatives were incubated together before
being run on native 12.5% PAGE gels. Addition of either RIN4142–211 or
RIN4142–179 fragments with AvrB resulted in slower band migration (indicated
by *). (C) Confirmation of the RIN4142–179 fragment as the AvrB interacting
domain was made by native gel filtration and subsequent SDSPAGE of the
relevant fractions. St, starting mixture of AvrB and RIN4142–179. No other
fractions contained either protein.
6500  www.pnas.orgcgidoi10.1073pnas.0500792102 Kim et al.
AvrRpt2 to inhibit RPM1 activation by AvrRpm1 or AvrB. RCS1
mutation had no effect. Hence, the observation that AvrRpt2
can interfere with AvrRpm1- or AvrB-mediated activation of
RPM1 is clarified: AvrRpt2 cleaves RIN4 at RCS2, releasing it
from the membrane, disrupting proper RPM1 localization and
accumulation. This cleavage blocks the ability of AvrRpm1 or
AvrB to activate RPM1. Consistent with these data, we found
that AvrB interacts with a small RIN4 142–179 fragment con-
taining RCS2. There was no interaction with various RIN4
fragments containing RCS1. Strikingly, then, at least two type III
effectors have evolved to target not only the same host protein,
but the same subdomain within that protein.
The targeting of multiple, related host factors by a type III
effector may contribute to efficient virulence, compared to the
targeting of a single host protein. We discovered a small family
of 11 Arabidopsis proteins that share with RIN4 a conserved
‘‘nitrate-induced’’ (NOI) domain (pfam05627.3) containing both
the RCS and the AvrB binding domain of RIN4. The NOI
domain is conserved in small families of otherwise unrelated
proteins in both monocots and dicots, suggesting that it has a
conserved, plant-specific function. The Arabidopsis proteins
(Table 1, which is published as supporting information on the
PNAS web site) contain either one or two (NOI10 and NOI11)
RCS consensus sequences; we predict that most, but not all, will
be cleaved by AvrRpt2. NOI10 and NOI11 are clearly related by
duplication. The RCS2 sequence from each deviates significantly
from the consensus, suggesting that these will not be AvrRpt2
cleavage sites. Similarly, some, but not all, are predicted to bind
AvrB. We find possible palmitoylation or prenylation sequences
in all 11 NOI proteins, supporting our contention that these
proteins are all acylated into the host plasma membrane.
We propose that the NOI domain proteins have conserved
functions in regulation of plant defense responses and that these
are targets for at least AvrRpt2, AvrRpm1, and AvrB. For
example, an NOI-containing protein from Nicotiana benthami-
ana (orthologous to At5g55850; NOI4) was required for HR
induced through the NB-LRR protein Prf (21). Furthermore,
RIN4 overexpression suppresses basal defense responses, and
the elimination of RIN4 (in a rin4 rpm1 rps2 triple mutant) leads
to enhanced basal defense responses (22). Manipulation of RIN4
and other NOI-containing proteins at the highly conserved NOI
domain by AvrRpt2, AvrRpm1, and AvrB may modulate the
plant immune system. Because the RCS consensus and the
domain that binds AvrB are largely conserved across the small
NOI family, we speculate that the conserved sequences are
required for the ancestral RIN4 and NOI domain function.
Cleavage of RIN4 by AvrRpt2 at RCS2 removes most of RIN4
from the membrane, presumably altering interactions with, and
regulation of, both RPM1 and RPS2. For example, when RIN4
levels are decreased, RPS2 and RPM1 are activated, and levels
of RPM1 are proportionally diminished (9, 15). Both AvrRpm1
and AvrB require myristoylation for their localization at the
plasma membrane and function (13). The membrane localized,
enzymatically active fragment of AvrRpt2 also carries an N-
terminal myristoylation site, G72. Both RPM1 and RPS2 require
the glycosylphosphatidylinositol-anchored NDR1 protein for
their function (23, 24). Acylated proteins are commonly found in
membrane subdomains, or lipid rafts. Thus, it is increasingly
likely that a set of acylated proteins assembled into a lipid
microdomain plays a key role in activation of the plant immune
system. This finding would be consistent with type III effectors
from animal pathogens that target lipid microdomains for their
function in manipulating host cell physiology (25, 26).
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